AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$19.35 USD
+0.11 (0.57%)
Updated Jun 29, 2022 04:00 PM ET
After-Market: $19.35 0.00 (0.00%) 4:26 PM ET
3-Hold of 5 3
C Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ANGO 19.35 +0.11(0.57%)
Will ANGO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ANGO based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANGO
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag
ANGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aspira (AWH) Reports Q4 Loss, Lags Revenue Estimates
New Strong Sell Stocks for March 8th
Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates
Other News for ANGO
AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022
AngioDynamics to Present at the UBS Global Healthcare Conference
AngioDynamics to Present at the BofA Securities Healthcare Conference
AngioDynamics Shows Progress In Still-Challenging Times
AngioDynamics price target raised to $40 from $34 at Canaccord